NCT06811805 - Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

February 23, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2028

Conditions

AKI - Acute Kidney InjuryCardiac Surgery Associated - Acute Kidney Injury

Interventions

DEVICE

RenalGuard Therapy

OTHER

Standard of Care (SOC)

Standard of care

Trial Locations (8)

RECRUITING

Jessa Medica Center, Hasselt

RECRUITING

TUM Klinikum Deutsches Herzzentrum, Munich

RECRUITING

Uniklinikum Munster, Münster

RECRUITING

Rambam Medical Center, Haifa

RECRUITING

Rabin Medical Center - Belinson Campus, Petah Tikva

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

RECRUITING

Sahlgrenska University Hospital, Gothenburg